Phillip Benjamin (Ben) Berry Sells 645 Shares of Enovis Co. (NYSE:ENOV) Stock

Posted by Defense World Staff on Jun 4th, 2023

Enovis Co. (NYSE:ENOV – Get Rating) CFO Phillip Benjamin (Ben) Berry sold 645 shares of the firm’s stock in a transaction dated Friday, June 2nd. The shares were sold at an average price of $54.17, for a total transaction of $34,939.65. Following the completion of the transaction, the chief financial officer now directly owns 20,223 shares in the company, valued at $1,095,479.91. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Phillip Benjamin (Ben) Berry also recently made the following trade(s):

On Monday, March 20th, Phillip Benjamin (Ben) Berry sold 600 shares of Enovis stock. The shares were sold at an average price of $51.84, for a total transaction of $31,104.00.

Enovis Stock Performance

NYSE:ENOV opened at $56.24 on Friday. The stock has a market cap of $3.07 billion, a P/E ratio of -58.58 and a beta of 2.02. The company has a current ratio of 2.38, a quick ratio of 1.13 and a debt-to-equity ratio of 0.08. The stock’s 50-day moving average is $55.21 and its 200-day moving average is $56.35. Enovis Co. has a 1-year low of $43.88 and a 1-year high of $68.15.

Enovis (NYSE:ENOV – Get Rating) last released its quarterly earnings results on Thursday, May 4th. The company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.07. Enovis had a positive return on equity of 3.70% and a negative net margin of 3.24%. The company had revenue of $406.20 million for the quarter, compared to analysts’ expectations of $389.95 million. During the same period in the previous year, the business posted $0.37 earnings per share. The business’s quarterly revenue was up 8.2% compared to the same quarter last year. Equities research analysts anticipate that Enovis Co. will post 2.27 earnings per share for the current year.

Analysts Set New Price Targets

ENOV has been the topic of a number of recent analyst reports. Wells Fargo & Company raised shares of Enovis from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $55.00 to $67.00 in a research note on Friday, May 12th. Robert W. Baird lifted their target price on Enovis from $64.00 to $67.00 in a research report on Friday, May 5th. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $65.00 target price on shares of Enovis in a research report on Tuesday, March 28th. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $64.88.

Institutional Trading of Enovis

Several institutional investors have recently modified their holdings of ENOV. T. Rowe Price Investment Management Inc. boosted its holdings in Enovis by 0.5% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 6,040,170 shares of the company’s stock valued at $323,270,000 after acquiring an additional 30,198 shares during the last quarter. BlackRock Inc. boosted its holdings in Enovis by 4.9% in the first quarter. BlackRock Inc. now owns 5,174,172 shares of the company’s stock valued at $276,766,000 after acquiring an additional 241,816 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Enovis by 1.0% in the third quarter. Vanguard Group Inc. now owns 4,482,428 shares of the company’s stock valued at $206,505,000 after acquiring an additional 43,799 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in Enovis by 5.0% in the first quarter. Dimensional Fund Advisors LP now owns 2,902,004 shares of the company’s stock valued at $155,227,000 after acquiring an additional 139,205 shares during the last quarter. Finally, Durable Capital Partners LP boosted its position in Enovis by 1.3% during the fourth quarter. Durable Capital Partners LP now owns 2,714,032 shares of the company’s stock valued at $145,255,000 after acquiring an additional 34,825 shares during the last quarter. Institutional investors own 96.73% of the company’s stock.

About Enovis

(Get Rating)

Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries.